Annals of hematology · 2025

Matching-adjusted indirect comparison of CPX- 351 in secondary Acute Myeloid Leukemia between the registrative trial and a real-life study.

Сравнительное исследованиеСтатьяНазвание и аннотация: Перевод пока не подготовлен

Обработка статьи · этапы, ошибки и управление

Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Fianchi Luana, Piciocchi Alfonso, Guolo Fabio, Marchesi Francesco, Marsili Giovanni, Cattaneo Chiara, Gottardi Michele, Restuccia Francesco, Candoni Anna, Ortu La Barbera Elettra, Fazzi Rita, Pasciolla Crescenza, Finizio Olimpia, Fracchiolla Nicola, Delia Mario, Lessi Federica, Dargenio Michela, Bonuomo Valentina, Del Principe Maria Ilaria, Zappasodi Patrizia, Picardi Marco, Basilico Claudia, Piedimonte Monica, Minetto Paola, Chiusolo Patrizia, Prezioso Lucia, Buquicchio Caterina, Melillo Lorella, Zama Daniele, Farina Francesca, Mancini Valentina, Rondoni Michela, Busca Alessandro, Pagano Livio

Аннотация

A real-life study on CPX-351 and the standard arm ('7 + 3') of the CPX-351 registrative trial in adults with secondary Acute Myeloid Leukemia were compared by an unanchored Matching-adjusted indirect comparison (MAIC), in order to evaluate the efficacy and toxicity of CPX-351. Results of this study are important to confirm the role of CPX-351 in significantly improving survival and remission rates compared with '7 + 3' with a good safety profile in AML patients with high-risk features, a target group traditionally with a very poor prognosis. Moreover, this pilot analysis underlines the potentiality of the statistical method to compare studies with strong differences.

Предметные рубрики MeSH

Adult Aged Female Humans Male Middle Aged Antineoplastic Combined Chemotherapy Protocols Cytarabine Daunorubicin Leukemia, Myeloid, Acute Neoplasms, Second Primary Pilot Projects Registries Survival Rate

Matching-adjusted indirect comparison of CPX- 351 in secondary Acute Myeloid Leukemia between the registrative trial and a real-life study.

Ошибки и ограничения

Аннотация

Предметные рубрики MeSH